Upload
naser-tadvi
View
6.898
Download
4
Embed Size (px)
DESCRIPTION
Treatment of diabetes mellitus with description of drugs
Citation preview
Pharmacotherapy of Diabetes Mellitus
Dr Naser Ashraf TadviAssociate Professor
Kamineni Institute of Medical Sciences
Narketpally, Nalgonda
Diabetes• Diabetes is a group of metabolic
disorders characterized by chronic hyperglycemia associated with disturbances of carbohydrate, fat and protein metabolism due to absolute or relative deficiency in insulin secretion and/or action
• Diabetes causes long term damage, dysfunction & failure of various organs
Diagnosis of diabetes
• Fasting Plasma Glucose ≥ 126 mg / dl
• Symptoms of DM and a random blood glucose level of ≥ 200 mg/dl
• Oral glucose tolerance test– 2 hr after 75 gm glucose load ≥ 200 mg / dl
Classification of DiabetesProposed by ADA - 1997.
• Type I: – Absolute Insulin Deficiency due to islet cell
destruction • Either immune mediated or idiopathic
• Type II: – Relative insulin deficiency due to impaired -cell
function – Marked ↑ peripheral insulin resistance
• Type III: Other Specific types• Type IV: Gestational Diabetes
Other specific types
A) Genetic defects of Beta cell function
B) Genetic defects in Insulin action
C) Diseases of the Exocrine Pancreas
D) Secondary to Endocrinopathies
E) Drugs / Chemical induced
F) Infections
G) Uncommon form of Immune Mediated Diabetes.
H) Other Genetic Syndromes associated with Diabetes
MODY Syndromes
Lipo atrophic Diabetes
FCPDPancreatitis
TraumaNeoplasia
Cystic FibrosisHemochromatosis
AcromegalyCushings SyndromePheochromocytoma
HyperthyroidismSteroids
ThiazidesDiazoxide
Beta BlockersThyroid Hormones
Congenital RubellaCMV
Anti insulin Receptor Antibodies
Down’s SyndromeTurners
Klinefelters
Type 2 Diabetes
β cells : insulin 65-70 %cells : glucagon 25 %δcells : somatostatin 10 % PP (or F cells): pancreatic polypeptide 2 %
Physiology of Human Insulin
• Only 2% of the pancreas weight is endocrine. 98 % Exocrine
• Total number of Islets…. 1 lakh• Number of cell / Islet 1-2 thousand• Beta cells / Islet 65-70 %• Total Insulin storage 200 units• Daily insulin release 40 -50 units• 1 unit Insulin 8-10 gm. Glucose
Beta cell statistics
Insulin
Discovery of insulin
Patient leonard thomson.,, February 15, 1923 December 15 1922
The Miracle of Insulin
Biosynthesis of insulin
Preproinsulin
Proinsulin
Insulin
Structure of insulin
21 amino acids
30 AA
Difference between human, pork, beef insulin
Species A-chain B-chain
8th AA 10th AA 30th AA
Human THR 1LEU- THR
Pork THR ILEU ALA
Beef ALA VAL ALA
Cell at rest
Secretion of insulin > 70 mg/ml
GLUT 2
Bioassay of insulin
• 1 IU reduces the BSL to 45 mg/dl in fasting rabbits
• 1 mg insulin = 28 IU• Can also be measured by radioimmunoassay
or enzyme immunoassay
• Direct stimulation• Plasma glucose or Amino Acids , ketones
• Hormonal regulation• Gastrointestinal hormones (GIP, CCK)
directly stimulate β cells • Neural regulation
• Parasympathetic stimulates insulin release through IP3/ DAG
• Sympathetic NS inhibits insulin release through 2 receptor activation
Regulation of insulin secretion
Actions of insulin
Rapid actions Intermediary actions Long term
Sec / min Few hours > 24 hrs
E.g Metabolic actions
•↑ multiplication•↑ differentiation of cells • Imp role in intrauterine & extrauterine growth
Through DNAe.g • ↑ GLUT synthesis• Synthesis of enzymes for AA metabolism
Actions of insulin
• Metabolic: – carbohydrate, lipid , protein, electrolyte
• Vascular • Anti-inflammatory • Fibrinolytic• Growth • Steroidogenesis
Carbohydrate metabolism
• Over all action of insulin is to ↓ glucose level in blood – ↑ Transport of glucose inside the cell– ↑ Peripheral utilization of glucose – ↑ Glycogen synthesis– ↓ Glycogenolysis – ↓ Neoglucogenesis
Lipid metabolism
• ↓ Lipolysis • ↑ Lipogenesis • ↑ Glycerogenesis • ↓ Ketogenesis • ↑ Clearance of VLDL & chylomicrons from
blood through enzyme Vascular Endothelial Lipoprotein Lipase
Protein metabolism
• Protein synthesis • ↑ entry of amino acids in cells
Electrolyte metabolism
• ↑ transport of K+, Ca++, inorganic phosphates
Other actions
• Vascular actions: – Vasodilation ? Activation of endothelial NO
production • Anti-inflammatory action
– Especially in vasculature • Decreased fibrinolysis • Growth• Steroidogenesis
• Glucose transporters –
• GLUT 1 Non insulin mediated glucose
uptake• GLUT 3 • GLUT 2 – Beta cell – Glucose sensors
• GLUT 4 – Insulin mediated glucose uptake in
muscle & Adipose tissue
Mechanism of action of insulin
Insulin Mediated Glucose Transport
G
INS
aa
bb
InsulinRecepto
rComplex
INSaa bb
a subunit
b subunit
Insulin molecule
Storage vesiclecontaining
GLUT 4
Glucose
Tyrosine Kinase Activation
Metabolised
Stored as Glycogen
Fate of insulin • Distributed only extracellularly • Must be given parenterally • Addition of zinc or protein decreases its
absorption & prolongs the DOA • Insulin released from pancreas is in
monomeric form• Half life of insulin = 5 -9 minutes
Different types of insulin preparations
• Conventional preparations of insulin – Produced from beef or pork pancreas – 1 % of other proteins– Potentially antigenic
• Highly purified insulin preparations – Gel filtration reduces proinsulin (50-200PPM)
• Human insulins • Newer insulin analogs
Conventional insulin preparations Type Onset
(Hr)Peak (Hr)
DOA (Hr)
Short acting Regular insulin Semilente
0.5 -1 1
2-4 3-6
6-8 12-16
Intermediate acting
Lente Isophane(NPH) 1-2 8-10 20-24
Long acting Ultra lente Protamine Zinc Insulin (PZI)
4-6 14-18 24-36
Highly purified insulin preparations • Single peak insulins
– Purified by gel filtration contain 50 to 200 PPM proinsulin
– Actrapid: purified pork regular insulin – Monotard: purified pork lente – Mixtard: purified pork regular(30%) + isophane(70%)
• Mono component insulins– After gel filtration purified by ion exchange
chromatography contain 20 PPM proinsulin – Actrapid MC, Monotard MC
Human insulins
• Human (Actrapid, monotard, insulatard, mixtard)• Obtained by recombinant DNA technology • Advantages
– More water soluble as well as hydrophobic – More rapid SC absorption , earlier & more defined
peak – Less allergy
• Disadvantages – Costly – Slightly shorter DOA
Indications of human insulins
• Insulin resistance • Allergy to conventional preparations • Injection site lipodystrophy • During pregnancy • Short term use of insulin
Newer Insulin analogs
Type Onset Peak (Hr)
DOA (Hr)
Rapid acting Lispro Aspart Glulisine
5-15 min 10-15 min5-15 min
111
3-53-55-6
Long acting Glargine Detemir
1-2 hrs 2-3 hrs
No peak 6-8 hr
24 hr 24 hr
Insulin Lispro• Produced by Inversing proline at B28 with
lysine at B29. • Forms weak hexamers , dissociate rapidly • Needs to be injected immediately before,
during or even after meals • Better control of meal time glycemia & lower
incidence of PP hypoglycemia
• Insulin aspart:– Proline at B28 replaced by aspartic acid – Change reduces tendency for self aggregation
• Insulin glulisine– lysine replaces aspargine at B3 & glutamic acid
replaces lysine at position B29
Insulin glargine • Prepared by adding 1 glycine at A21 together
with 2 arginine residues at end of B chain • Improved Stability• Much better bioavailabilty • Smooth peakless effect is obtained • Fasting & interdigestive BGL effectively
lowered irrespective of time of day • Lower hypoglycemic episodes• Cannot be mixed with other insulins
Insulin detemir • Soluble long acting basal insulin analog with
flat action profile and prolonged duration • Threonine in B30 ommited & C14 fatty acid
chain attached to amino acid B29 • Prolonged action
– Strong self association – Albumin binding– Fatty acid side chain
Action Profiles of Insulins
0 1 2 53 4 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Plasmainsulinlevels
Regular 6–8 hours
NPH 12–16 hours
Ultralente 18–20 hours
Hrs
Aspart, glulisine, lispro 4–5 hours
Glargine ~24 hours
Detemir ~14 hours
Danne T et al. Diabetes Care. 2003;26:3087-3092
Insulin analogs score over conventional insulins
• Less nocturnal hypoglycemia• Less weight gain• Better efficacy (?)• More physiological action profiles• Less premeal lag time (0-15 mts)• Lispro & Glulisine even after meals• Better PP glucose control• Less intra-patient/inter-patient variability• Improved predictability, tolerability, and flexibility
Adverse effects of insulin
• Hypoglycemia • Local reactions
– Lipodystrophy – Lipoatrophy
• Allergy • Obesity• Insulin induced edema
Drug interactions of insulin
• Non selective beta blockers • Thiazides,furosemide, corticosteroids, OCP ,
nifedipine ↑ BSL• Alcohol Precipitates hypoglycemia • Salicylates, lithium, theophylline, may
accenuate hypoglycemia
Uses of insulin
• Diabetes mellitus – Must for type I diabetics – Can be used in type II diabetics
• Diabetic ketoacidosis • Hyperosmolar non ketotic hyperglycemic
coma
Indications of insulin in type II DM
• Primary or secondary failure of oral hypoglycemics
• Pregnancy• Perioperative period • CKD• Steroid therapy• LADA• Fasting > 300 mgms HbA1c > 10• Unintentional wt loss with or with out ketosis• Type 2 with DKA ( severe beta cell dysfunction)
Recommended sites for S/C Insulin injections
Initial Insulin dosage in T1DM
• 0.5 U/kg/day with negative to moderate ketones
• 0.7 U/kg/day with large ketones
Clinical case
• 14 yrs old, Chitra• 3Ps & weight loss – 10 days duration• RBS 418 mg %• 36 kg wt• No marked dehydration• T1DM- No ketoacidosis• Proceed?
Insulin dose for this child
• (0.5 U/kg/day with negative to moderate ketones)
• 36 kg wt• No ketoacidosis• 36 X 0.5 = 18 U/day
18 U/day as “Four-shot-per-day”
• Basal-Bolus therapy• Ideal for better control & flexible lifestyle• 50% Basal dose= 9 U at bedtime (NPH,G,D)• 50% Bolus dose = 9 U premeals (R,A,L,Glu) 3U Prebreakfast 3U Prelunch 3U Predinner
18 U/day as “Five-shot-per-day”
• Basal-Bolus therapy• Ideal for better control & flexible lifestyle but
“too many shots”• 50% Basal dose= 9 U divided as 5 U
prebreakfast + 4 U at bedtime (G or D)• 50% Bolus dose = 9 U premeals (R,A,L,Glu) 3U Prebreakfast 3U Prelunch 3U Predinner
18 U/day as “Two-shot-per-day”Split mixed regimen
• 2/3 prebreakfast (12 U)• 1/3 predinner (6 U)• Prebreakfast: 8 U NPH + 4 U Regular (A,L,G)• Predinner: 3 U NPH + 3 U Regular “8 N/4 R - 0 - 3N/3R”
18 U/day as “Three-shot-per-day”
• 2/3 prebreakfast (12 U)• 8 U NPH + 4 U Regular (A,L,Glu)
• 1/3 peridinner (6 U)• 3 U Regular ( or A,L,Glu) Predinner • 3 U NPH at bedtime
How to initiate insulin treatment in type 2
• Start with 0.2 units / kg (or)
• Body weight divided by 5 (or)
• Dose = FBS-50 (or) 10
• Average fasting blood sugar divided by 18
Continuous I.V. insulin infusion
• Admit the patient• Insulin I.V.drip• Achieve & maintain euglycemia• Calculate the insulin required for 12-24 hrs• 80% of that used as O.P. therapy• Ex., 40 U to maintain euglycemia for 24 hrs• 80% (30 U/day) used as outpatient therapy
Pathogenesis of DKA Insulin deficiency Absolute / relative
Counter hormone excess↓ Anabolism ↑ catabolism
↓Peripheral utilization of Glucose
Hyperglycemia
Heavy Glucosuria (osmotic diuresis)
Loss of water & electrolytes
↑ Glycogenolysis ↑ Glycolysis ↑Gluconeogenesis
Dehydration
+
Hyperosmolarity
↓ Fluid intake
Pathogenesis of DKA (How ketoacidosis occurs)
↑ FFA to liver
↑ Acetyl coA
↓ Alkali reserve
↑ Lipolysis
↑ Acetoacetyl coA
Acetoacetate -Hydroxy butrate Acetone
Hyperketonemia
Acidosis
Treatment of DKA
• Fluid therapy • Rapid acting regular insulin • Potassium • Bicarbonate • Phosphate • Antibiotics • Treatment of precipitating cause• General measures
Fluid therapy • Adequate tissue perfusion is necessary insulin
action • Normal saline is fluid of choice for initial
rehydration – 1 litre in first hour – Next 1 L in next 2 hours – 2 litres in next 4 hours – 2 litres in next 8 hours
• i.e 4 to 6 litres in 24 hours • When BSL reaches 300 mg% fluid should be
changed to 5 % dextrose with concurrent insulin
Insulin in DKA • Regular/ short acting insulin IV treatment of
choice • Loading dose = 0.1-0.2 U/kg IV bolus • Then 0.1 U /kg/hr IV by continuous infusion• Rate doubled if no significant fall in BSL in 2 hr• 2-3 U/hr after BSL reaches 300mg%• If patient becomes fully conscious encouraged
to take oral food & SC insulin started
Potassium replacement
• In initial stage of treatment potassium not administered because in DKA it remains normal or ↑
• In presence of insulin infusion Sr potassium ↓ hence 10 mEq/L potassium can be added with 3rd bottle of normal saline
• Sr K+ < 3.3 mEq/L : 20 -30 mEq/hr
Bicarbonates & phosphates
• Bicarbonates – If blood pH > 7.1 no need of sodium bicarbonate – In presence of severe acidosis 50 mEq of sodium
bicarbonate added to IV fluid • Phosphates
– Non availability of ideal preparation– Replacement not very essential unless < 1 mEq/L– potassium phosphate 5-10 m mol/hr
Hyperosmolar Non Ketotic Coma • Usually occurs in type II • Dehydration with severe hyperglycemia
without ketoacidosis, because insulin inhibits hormone sensitive lipase
• The general principle of T/t is same as for DKA except that pt needs more faster fluid replacement – Half NS preferred 2 Lit in 2 Hrs followed by 1 Lit in
next 2 hrs• Low dose heparin to prevent vascular
thrombosis & intravascular coagulation
Insulin resistance
• State in which normal amount of insulin produces subnormal amount of insulin response – ↓ insulin receptors – ↓ affinity for receptors
• May be acute or chronic • Requirement of > 200 Units of insulin per day
in absence of stress • Common in type II diabetics & obese
Newer insulin delivery devices
• Prefilled insulin syringes • Pen devices • Jet injectors • Inhaled insulin • Insulin pumps • External artificial pancreas • Insulin complexed with liposomes:
intraperitoneal, rectal, oral
40 units/ml 100 units/ml Tuberculin syringe
PEN INJECTORS• Easy to carry • Easier to accurately measure dose• more expensive than vials
JET INJECTORSNeedleless system. Uses high pressure air to force a tiny stream of insulin through the skin
Insulin Pump Pro• Simplified insulin
dosing• Precise delivery• Greater impact in those
with highest starting A1c
• Slightly less insulin use per day
Con• More DKA• More severe
hypoglycemia
Inhaled Insulin (Exubera) Advantages Improved pt convenience Faster onset of action compared to Regular SC insulin No needles risk of infection Potential earlier onset of insulin therapy in Type 2 DM
Oral antidiabetic drugs
• Sulfonylureas:• Meglitinides: • Biguanides :• Thiazolidinediones:• -glucosidase inhibitors:
Sulfonylureas I Generation
– Tolbutamide– Chlorpropamide
II Generation– Glipizide– Gliclazide– Glibenclamide (Glyburide) – Glimepiride
Mechanism of action
• Release of insulin by acting on SUR1 receptors • Primarily augment phase 2 of insulin secretion• Presence of at least 30% functional -cells
essential for their action.• Minor action: ↓ glucagon secretion • Extra pancreatic action: ↑sensitivity of
peripheral tissue to insulin by ↑insulin receptors
Pharmacokinetics
• Well absorbed orally • Highly bound to plasma proteins > 90% • Have low volume of distribution • Cross placenta C/I in pregnancy • Metabolized in liver• Excreted in urine
Daily dose & Duration of action
Sulfonylureas Doses No of doses/day
DOA (hrs )
1 Tolbutamide 0.5 – 2 g 2-3 6-82 Chlorpropramide 0.1 to 0.5 g 1 36 -48 3 Glibenclamide 5 to 15 mg 1-2 18-24 4 Gliclazide 40- 240 mg 1-2 12-245 Glipizide 5 to 40 mg 1-2 12-186 Glimepiride 1 to 6 mg 1 Upto 24
Individual Sulfonylurea Sulfonylureas Special points
1 Tolbutamide Short acting, low potency , hypoglycemia least likely
2 Chlorpropramide ↑Hypoglycemia, ↑ADH , Disulfiram Like Reaction, Cholestatic jaundice
3 Glibenclamide Potent but slow acting, may work when others fail
4 Gliclazide Antiplatelet, antioxidant action, may delay Retinopathy, less weight gain
5 Glipizide Fast acting, hypoglycemia & weight gain less likely, prefered in elderly
6 Glimepiride More extrapancreaatic action, less hyperinsulinemia, less hypoglycemia
GLIMEPIRIDE
1) Lesser risk of hypoglycemia2) Insulin sparing effect (Significant extra pancreatic
effects)3) Relatively safe in elderly and mild renal failure4) Antiplatelet and antifibrinolytic activity5) Little or no weight gain6) FDA approved combination therapy with insulin7) Safe and effective for use in the pediatric
population8) ↑ Levels of plasma adiponectin & ↓ TNF α9) Stimulates GLUT4 expression
Why Glibenclamide is more potent and longer acting than other SU
1. May accumulate within cells and directly stimulate exocytosis of insulin granules
2. Greater/longer binding to SUR-1 receptors
3. Slower absorption and distribution
4. Inhibition of hepatic insulinase
5. Suppression of several counter-regulatory hormones
6. More suppression of HGO
7. May stimulate insulin synthesis
Adverse effects
• Hypoglycemia:• GI disturbances: Nausea, vomiting, metallic
taste, diarrhoea & flatulence • Weight gain • Hypersensitivity • Not safe in pregnancy • Chlorpropamide:
– cholestatic jaundice, dilutional hyponatremia, antabuse reaction
Contraindications 1. Allergy to SU
2. Renal failure:
3. Significant hepatic dysfunction
4. Severe infections, stress, trauma, major
surgery, CVA, AMI
5. Pregnancy (except Glibenclamide)
6. T1DM
Drug interactions
• Drugs that ↑ SU action – Salicylates, sulfonamides – Cimetidine , warfarin, sulfonamides – Propranolol
• Drugs that ↓ SU action – Phenytoin, phenobarbitone , rifampicin – Corticosteroids, thiazides, furosemide, OCP
Selection of SUClinical conditions Agents
Fasting & postprandial hyperglycemia
Long acting/Intermediate acting Su.
Only postprandial hyperglycemia Glipizide
Renal impairment Glipizide
GDM Glibenclamide
Elderly (> 65) Avoid Glibenclamide, chlorpropamide
Alcoholics Avoid chlorpropamide
DM & IHD Avoid Glibenclamide.
DM, HT & Edema legs Avoid chlorpropamide
SU + other antihyperglycemic agents SU + Metformin (best)
SU + Glitazones (best)
SU + AGI (better)
SU + 2 or more drugs (good)
SU + Insulin (good)
SU + Meglitinides (bad)
SU + SU (worst)
Meglitinide analogs
• Quick & short acting insulin releasers • MOA: same as Sulfonylureas but act through
different receptor SUR2 • Mainly used to control Post prandial
hyperglycemia • Less hypoglycemia
Repaglinide
• Well tolerated in elderly patients in renal impairment
• Adverse effects: – Mild headache, dyspepsia, arthralgia, headache
• Indicated in type II DM • Dose : start 0.5mg with meals can ↑ 16mg/day
Nateglinide • Stimulates first phase of insulin secretion • More rapid acting & shorter duration than
repaglinide • Mainly used in post prandial hyperglycemia
without producing late phase hypoglycemia • Little effect on fasting BSL • Adverse effects: diziness, nausea, flu like
symptoms • Dose: 60 to 180 mg TDS with meals
Biguanides
• Metformin & phenformin• Little or no hypoglycemia• Also improves the lipid profile in type II
diabetic patients • Metformin dose = 0.5 to 2.5 g/day in 2-3
divided doses
Mechanism of action
• Suppress hepatic & renal gluconeogenesis• ↑ uptake & utilization of glucose by skeletal
muscles which reduces insulin resistance • Inhibit alimentary absorption of glucose• Interfere with mitochondrial respiratory chain
& promote peripheral glucose utilization by enhancing anaerobic glycolysis
Pharmacokinetics
• Taken orally , well absorbed through GI tract • Not metabolized at all • Excreted unchanged in urine
METFORMIN - INDICATIONS
• Obese Type 2 Diabetes.
• Secondary Sulfonylurea Failure state.
• To reduce Insulin requirements.
• Can be combined with Sulfonylureas, Glitazones, Insulin.
Adverse effects • Anorexia, nausea, vomiting, diarrhoea• Metallic taste • Loss of weight • Skin rashes • Lactic acidosis: rare • Vitamin B12 deficiency: due to malabsorption Usually does not cause hypoglycemia even in
large doses
Contraindications of metformin • Renal failure –
( Sr. Crt > 1.5 / Crt. Clearance < 40
• Advanced Liver Disease.
• Alcohol abusers.
• Cardiac Disease.
• Pregnancy.
Thiazolidinediones (Glitazones) Rosiglitazone & pioglitazone Selective agonists of PPAR
Bind to nuclear PPAR
Activate insulin responsive genes - regulate carbohydrate & lipid metabolism
Sensitize the peripheral tissues to insulin
↓blood glucose by
↑ Glucose transport into muscle & adipose tissue
Inhibit hepatic gluconeogenesis
Promote lipogenesis
Thiazolidinediones• Hyperglycemia, hyperinsulinemia, and
elevated HbA1c levels are improved. • Pioglitazone has no effect on LDL levels, ↓
triglyceride & ↑ HDL • Rosiglitazone has inconsistent effect on lipid
profile it ↑ HDL & LDL levels• The TZDs lead to a favorable redistribution of
fat from visceral to subcutaneous tissues.
Pharmacokinetics
• Both Rosiglitazone & pioglitazone are completely absorbed from GIT
• Highly bound to plasma proteins (>95%) • Rosiglitazone metabolized by CYP2C8,
Pioglitazone metabolized by CYP2C8 & CYP3A4• Drug interactions less with rosiglitazone • Metabolites of rosiglitazone are excreted in
urine and those of pioglitazone in bile
• Pioglitazone: – 15 to 45 mg once daily orally
• Rosiglitazone: – 4 to 8 mg once daily orally
• Pt who benefit most are type II DM with substantial amount of insulin resistance
• Also used in PCOD • Monotherapy – Hypoglycemia rare • Add-on Therapy – readjust dosage.• Takes one month to act
Adverse effects
• Weight gain: due to fluid retention & edema • ↑ Extracellular fluid volume • Worsening of CHF • ↑ Deposition of subcutaneous fat • Mild anemia: due to hemodilution • Hepatotoxicity : rare • Rosiglitazone: ↑risk of fractures especially in
elderly women
Contraindications
• Liver disease • Congestive heart failure • Pregnancy • Lactating mother • Children
Alpha glucosidase inhibitors
• Acarbose • Miglitol • Voglibose
104
Dietary Carbohydrates (Starch)
glucosidase enzymes (in the lining of cells of intestinal villi)
Pancreatic amylase
Absorbed in lower part of intestine
Monosaccharides (Glucose, fructose)
Oligosaccharides/ Disaccharides
Maltose, Isomaltose, Sucrose
X
Glucosidase inhibitors
Mechanism of action
Acarbose• Complex oligosaccharide • Inhibits -glucosidase as well as -amylase • Reduces postprandial hyperglycemia without
increasing insulin levels• Regular use reduces weight • In prediabetics reduces occurrence of type II
DM, hypertension & cardiac disease• Dose: 50 to 100 mg TDS • Given just before food or along with food
Adverse effects
• Flatulence, diarrhoea, abdominal pain• Do not cause hypoglycemia by themselves but
may cause if used with Sulfonylureas • If hypoglycemia occurs should not be treated
with routine sugar (sucrose),• Glucose should be used Contraindicated in inflammatory bowel disease
& intestinal obstruction
107
Voglibose
• Advantages over Acarbose and Miglitol– 20-30 times more potent then acarbose– Does not affect digoxin bioavailability unlike
acarbose– No dosage adjustment required in renal
impairment patients unlike miglitol– Superior tolerability– Dose: 0.2 to 5 mg
Newer drugs for Type II DM
• GLP-1 Analogues – Exenatide– Liraglutide
• DPP-IV Inhibitors– Sitagliptin– Vildagliptin– Alogliptin
• Amylin analog:Pramlintide
Exenatide
• Synthetic GLP I analogue resistant to DDP IV • ↑ Post prandial insulin release• Supresses glucagon release • Supresses appetite and slows gastric emptying• injected SC twice daily 1 hour before meals
acts for 6 to 10 hours • Nausea is important side effect
Sitagliptin
• Orally active inhibitor of DPP-4 • Prevents degradation of endogenous GLP-I• Dose: 100mg a da• Mainly used in post prandial hyperglycemia • No action on weight and lipids • Costly
Pramlintide
• Synthetic amylin analog• Improves overall glycaemic control,↓ PPG• Reduces BW : anorectic action • Well tolerated • Given SC before meals • SE: GI disturbances/Less hypoglycemia when
used alone• Can be used in type I DM
Principles of treatment of Type 2 DM
Grade Diabetes Mellitus as mild, moderate or severe NB: FBG (150 -200 ---mild ) HbA1c < 8 ( 200-250 --- Moderate) HbA1c 8 - 9 ( more than 250 severe) HbA1c 9 - 10For severe DM start on insulin if there is wt loss &
ketosisFor mild & moderate DM use metformin if obese &
sulfonylureas if not obese
• Classify obese non obese
• Assess Liver function is normal or
abnormal
• Assess the kidney function
Principles of treatment of Type 2 DM
If diabetes not controlled
Look for SU failure Occult infection – TB – UTI Drug history and compliance Food history – hypoglycaemia
and compliance
cardiac problem – avoid glitazones if in failure avoid metformin Renal problem – avoid metformin
Liver problem – avoid glitazone and metformin In general
patients with complication
Short acting SU or insulin
Be ware of other drugs - Diuretics
- Corticosteroid
- Other hormones
- ACE inhibitors